European Dermatology Forum recommends Leo Pharma drug in line with other biologics

The guiding dermatological organization has put Leo Pharma’s eczema drug, Adtralza, in the same class as other biologics. Recently, England and Wales differed in opinion when recommending it as a second-line treatment.

Photo: Leo Pharma / PR

Over the summer, Leo Pharma can celebrate something of a milestone for its newest drug, Adtralza.

The European Dermatology Forum (EDF), a non-profit firm providing dermatological guidelines in Europe, has released a new set of recommendations for the treatment of atopic eczema. In the so-titled Euroguiderm Guideline, the EDF now recommends Leo Pharma’s Adtralza (tralokinumab) next to other biological medicines for the moderate-to-severe skin disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs